• LAST PRICE
    2.6300
  • TODAY'S CHANGE (%)
    Trending Down-0.0804 (-2.9664%)
  • Bid / Lots
    2.6500/ 1
  • Ask / Lots
    2.8500/ 1
  • Open / Previous Close
    2.7700 / 2.7104
  • Day Range
    Low 2.6201
    High 2.7700
  • 52 Week Range
    Low 2.3400
    High 4.2500
  • Volume
    789
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.7104
TimeVolumeELYM
09:32 ET1002.77
10:06 ET3702.6201
10:15 ET1002.63
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesELYM
Eliem Therapeutics Inc
72.2M
-1.8x
---
United StatesPASG
Passage Bio Inc
71.3M
-0.6x
---
United StatesTPST
Tempest Therapeutics Inc
71.2M
-1.7x
---
United StatesNVNO
enVVeno Medical Corp
73.5M
-2.6x
---
United StatesCTCX
Carmell Corp
69.5M
30.9x
---
United StatesIMMX
Immix Biopharma Inc
75.2M
-3.3x
---
As of 2024-02-22

Company Information

Eliem Therapeutics, Inc. is a biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. It is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver improved therapeutics for patients with these disorders. Its lead program is ETX-123, a Kv7.2/3 potassium channel opener. Kv7.2/3 has been clinically validated as a therapeutic target for both epilepsy and pain, with further encouraging clinical data in depression. Its ETX-123 lead candidate is an generate new chemical entities designed to harness the efficacy of the Kv7.2/3 channel mechanism while attempting to improve the safety and tolerability relative to earlier molecules, based on its insights into the mechanisms of toxicity and the potency and selectivity profile.

Contact Information

Headquarters
2801 CENTERVILLE ROAD 1ST FLOOR PMB #117WILMINGTON, DE, United States 19808
Phone
425-276-2300
Fax
302-636-5454

Executives

Executive Chairman of the Board, Interim Principal Executive Officer
Andrew Levin
Executive Vice President - Research and Development, Chief Scientific Officer
Valerie Morisset
Chief Accounting Officer
Emily Pimblett
Lead Independent Director
Liam Ratcliffe
Independent Director
Judith Dunn

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$72.2M
Revenue (TTM)
$0.00
Shares Outstanding
27.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.48
Book Value
$4.84
P/E Ratio
-1.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.